From Grok:
The X post by epidemiologist Nicolas Hulscher highlights a 2025 study where Ewingella americana, isolated from Japanese tree frog guts, achieved 100% complete tumor regression in mice with colorectal cancer after a single intravenous dose.
In the JAIST-led research using Colon-26 tumor-bearing mice, the bacterium outperformed anti-PD-L1 immunotherapy and doxorubicin chemotherapy via dual mechanisms: selective proliferation (3000-fold) in hypoxic tumors for direct cytotoxicity and activation of T cells, B cells, and neutrophils for immune attack.
The treatment showed rapid bacterial clearance from blood within 24 hours, no significant organ toxicity or long-term side effects at effective doses, and induced durable immunity as rechallenged mice rejected new tumors.
Leave a Reply